Current volatility and the upcoming surge and shift in elective surgeries is forcing medical device company leaders to rethink existing business models.
“Flatten the curve” has become the mantra of Covid-19 response resulting in stay-at-home advisories excluding essential travel, social distancing, and postponing elective surgeries.
Bain & Company's research suggests that surgeons at ASCs are more likely to change medical devices than their peers within hospital settings.
Have you or someone you know experienced an antimicrobial resistant infection? The most common is MRSA (methicillin-resistant Staphylococcus aureus), and this type of threatening infection is on the rise nationwide.
A case study by Relatable Healthcare.
Beginning in 2012, average year-over-year hospital costs have grown at a rate exceeding revenue growth. Pressure to maintain healthcare spending continues to intensify and supply chain costs have reached an all-time high.
The FDA’s Alternative Summary Reporting Program allowed inefficient reporting of injuries and deaths caused by medical device malfunction, and hid decades worth of important device data from doctors and the public.
"I’m confused about all of these biologic bone grafting products."
If you are a healthcare provider or administrator dealing with spine surgery, you have probably heard this statement before. You might have even said it yourself.
Modern technology has revolutionized countless industries over the last few decades including finance, retail, automobiles, and even Major League Baseball.
This month, OrthoKnow mentioned Relatable Healthcare in their publication Strategic Insights into the Orthopedic Industry 2019: Capitalize on Opportunities in the Emerging Outpatient Surgery Market.